Preclinical IV busulfan dose-finding study to induce reversible myeloablation in a non-human primate model

In this study we utilized a large animal model to identify a dose of intravenous busulfan that can cause reversible myelosuppression. Nine baboons (Papio anubis) were treated with IV busulfan at 6.4 (Group A), 8 (Group B), or 9.6 mg/kg (Group C). Peripheral blood counts were measured up to 90 days a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahmud, Nadim, Khanal, Amit, Taioli, Simona, Koca, Emre, Gaitonde, Sujata, Petro, Benjamin, Sweiss, Karen, Halliday, Lisa, Wang, Xinhe, Patel, Pritesh, Rondelli, Damiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264479/
https://www.ncbi.nlm.nih.gov/pubmed/30496309
http://dx.doi.org/10.1371/journal.pone.0206980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264479/
https://www.ncbi.nlm.nih.gov/pubmed/30496309
http://dx.doi.org/10.1371/journal.pone.0206980

Ejemplares similares